Kathryn Ryan, DO
Family Medicine · Anchorage, AKNPI 1629418215
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$566
- Novo Nordisk$492
- Astellas Pharma US Inc$348
- GSK$232
- Lilly USA, LLC$215
- plus $2K from 36 others
What the payments were for
- Food & beverage$4,63197%
- Education$1223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,753 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $85,904 |
| EliquisApixaban | 32 | $47,022 |
| MyrbetriqMirabegron | 40 | $37,077 |
| JardianceEmpagliflozin | 22 | $35,815 |
| JanuviaSitagliptin Phosphate | 41 | $34,105 |
| RybelsusSemaglutide | 16 | $26,496 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $22,340 |
| TrulicityDulaglutide | 23 | $21,938 |
| XareltoRivaroxaban | 18 | $21,170 |
| InvokanaCanagliflozin | 11 | $18,096 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $14,714 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $9,512 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $8,170 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,326 |
| FarxigaDapagliflozin Propanediol | 11 | $7,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $492 | $112,40097 claims |
| PfizerEliquis | $154 | $47,02232 claims |
| Johnson & JohnsonXarelto, Invokana | $82 | $39,26629 claims |
| Astellas Pharma US IncMyrbetriq | $348 | $37,07740 claims |
| MerckJanuvia | $94 | $34,10541 claims |
| Lilly USA, LLCTrulicity | $215 | $21,93823 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $566 | $21,91527 claims |
| GSKBreo Ellipta | $232 | $7,32619 claims |
| AbbVieSynthroid | $1,036 | $7,03462 claims |
| Sanofi-aventis U.S. LLCLantus | $97 | $1,34512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.
Other family medicine in Anchorage
- Mary FolandAnchorage$15K
- Ilona FarrAnchorage$14K
- Eric MiknichAnchorage$13K
- Allison KelliherAnchorage$6K
- Bruce KiesslingAnchorage$5K
- Bruck CliftAnchorage$5K
- Ulyana StiassnyAnchorage$4K
- Pebbles ShanleyAnchorage$4K
- Kenneth MollAnchorage$3K
- Jane SimonoAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.